source
- GSK to spend up to $1.3 billion on Hutchmed's dual-target cancer therapyGSK announced a deal to acquire the majority rights to Hutchmed's experimental therapy HMPL-A830. The agreement includes an upfront payment of $110 million and potential milestone and royalty payme…
- Health tech investors shift focus to larger funding rounds, Cityblock secures $116 millionThroughout the past year, investors in digital health have increasingly favored megafunding rounds rather than smaller seed or Series A deals. In August, community-health startup Cityblock announc…